Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Third party request |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Characterization |
| Species: | Human |
| Stage: | Assays completed |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
NA
Description
CAVD 849 (RiboMab_005) is a monoclonal antibody screening study evaluating scFv-Fc variants based on broadly neutralizing antibodies, PGT121-LS, PGDM1400-LS, and 1-18-LS, in BioNTech’s RiboMab platform.
Sign in to see full information about this study and to download study data.
Products
No Products used in studyIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.